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Summary. Adenine phosphoribosyltransferase (APRT) 
deficiency causing 2,8-dihydroxyadenine urolithiasis and 
renal failure is present at a high frequency among the 
Japanese but not other ethnic groups. A special type of 
mutant allele, designated APRT*J,  with a nucleotide 
substitution at codon 136 from ATG (Met) to ACG 
(Thr) is carried by approximately 79% of all Japanese 
2,8-dihydroxyadenine urolithiasis patients. We analyzed 
mutant alleles of 39 APRT deficient patients using a spe- 
cific oligonucleotide hybridization method after in vitro 
amplification of a part of the genomic APRT sequence. 
We found that 24 had only APRT*J alleles. Determina- 
tion of the haplotypes of 194 APRT alleles from control 
Japanese subjects and of the 48 different APRT*J alleles 
indicated that normal alleles occur in four major hap- 
lotypes, whereas all APRT*J  alleles occur in only two. 
These results suggest that all APRT*J  alleles have a 
single origin and that this mutant sequence has been 
maintained for a long period, as calculated from the fre- 
quency of the recombinant alleles. 
Introduction 
Recent studies analyzing genes of various genetic dis- 
eases at the molecular level have provided clues as to 
how such disease-causing genes are generated and main- 
tained. Among such genetic diseases, some are present 
at high frequencies in some ethnic groups but not others. 
These diseases have been the focus of special interest 
since common mutational alleles in different families 
within each ethnic group often have the same origin. 
Based on such data, the evolutionary history of each mu- 
tation can be studied. In the present investigation, we 
focussed on one such disease, adenine phosphoribosyl- 
transferase (APRT) deficiency. 
There are two known types of homozygous APRT 
deficiency causing 2,8-dihydroxyadenine urolithiasis and 
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renal failure (type I and type II; Simmonds et al 1989). 
The type I patients show virtually no APRT activity, 
whereas the type II patients have a partial deficiency 
(Simmonds et al. 1989). Although type I patients have 
been found among both Caucasian and Japanese popula- 
tions, type II patients have thus far been found only 
among Japanese (Simmonds et al. 1989; Kamatani et al. 
1987b); 79% of all the families with homozygous APRT 
deficiency were of type II (Kamatani et al. 1987b). In 
addition, over 70% of all families with 2,8-dihydroxy- 
adenine urolithiasis reported in the literature have been 
Japanese (Simmonds et al. 1989; Kamatani et al. 1988). 
In previous studies, a mutant enzyme was found in all 
type II patients examined; it had the same altered kinetic 
properties, including a reduced affinity for the substrate 
5-phosphoribosyl-l-pyrophosphate (PRPP) (Fujimori et 
al. 1985). The mutant allele, designated APRT*J, coding 
for this mutant enzyme had a nucleotide substitution at 
codon 136 (ATG to ACG) (Hidaka et al. 1988, 1989), 
and the disappearance of Met at position 136 in the 
amino-acid sequence was accordingly shown (Kamatani 
et al. 1989). 
It is clear that nucleotide substitution at codon 136 
(ATG to ACG) is the disease-causing mutation, as op- 
posed to a rare linked polymorphism, since all individu- 
als with type II APRT deficiency synthesize mutant 
APRT protein (Kamatani et al. 1987b, 1989), and the 
nucleotide substitution at codon 136 is the only amino- 
acid-changing substitution seen in the APRT*J allele 
(Hidaka et al. 1988). Additional evidence revealed that 
the predicted amino-acid substitution is within the puta- 
tive PRPP binding site of the enzyme (Dush et al. 1985; 
Hershey and Taylor 1986), and the mutant protein coded 
for by APRT*J has a reduced affinity for PRPP (Fuji- 
mori et al. 1985). All other mutant alleles from Japanese 
APRT deficient patients so far identified synthesized no 
enzyme protein, and were designated as APRT*QO 
(Fujimori et al. 1985). 
We report here the historical interrelation between 
the APRT*J mutation and very tightly linked poly- 
morphic markers. 
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Materials and methods 
Diagnosis of  APR T deficiency 
Diagnosis of APRT deficiency was made by the determination of 
the enzyme activity in hemolysates and the culture of viable T-cells 
with 6-mcthylpurine (Kamatani et al. 1985). Thus, when viable T- 
cells from patients were resistant to 6-methylpurine, they were 
diagnosed as homozygotes (both of the two alleles are defective). 
When the APRT activities determined in the hemolysates were 
completely deficient, the patients were classified as type I. When 
they were only partially deficient, the patients were classified as 
type II (Simmonds et al. 1989). 
In vitro amplification of the APR T-specific sequence 
DNA was extracted from mononuclear cells from blood samples or 
cells from B cell lines obtained from different subjects. A part of 
the APRT gene in these samples was amplified in vitro by the poly- 
merase chain reaction (PCR) (Saki et al. 1986) using synthetic 
primers PN-5 (5'GATGATCTGCTGGCCACTGG3') and PN-9 
(5 'CAGCTGGAGATGTrGGGCTG'3) (see Fig. 1 for the loca- 
tions of these sequences in human APRT DNA) and Taq DNA 
polymerase (Perkin Elmer Cetus, Norwalk, Conn., USA). PN-5 
has a nucleotide sequence of 1812 to 1831 of the sense strand of the 
human genomic APRT sequence ("A" in the initiation codon 
ATG was counted as position 1), whereas PN-9 anneals to nucle- 
otides 2238 to 2219 of the sense strand. The temperatures and time 
used for heat-denaturing, annealing and polymerizing steps were 
94~ 65~ and 72~ for 2, 3 and 3 rain, respectively. These steps 
were repeated for 35 cycles. The combination of primers PN-5 and 
PN-9 succesfully amplified the target 427-bp sequence, which in- 
cludes the APRT*J mutation site located at position 2069. When 
the amplification was successful, amplified bands could be vis- 
ualized with ethidium bromide after 3% agarose gel electrophore- 
sis. 
Sequence-specific oligonucleotide hybridization 
After blotting the amplified DNA on nylon membranes (Biodyne 
A, PALL Biosupport, N. Y.), dot hybridization was performed us- 
ing radiolabeled oligonucleotides as probes. Thus, PN-3 (5'CAG- 
GAACCACGAACGCTGC3') for APRT*J-specific and PN-4 (5' 
CAGGAACCATGAACGCTGC3') for normal (non-APRT*J) 
32 sequences were end-labeled with [? P]ATP (6000Ci/mmol) and 
T4 polynucleotide kinase, and hybridized with the amplified DNA 
blotted on the membranes. The methods for the hybridization and 
wash procedures were as described by Saiki et al. (1986) except 
that the washing temperature was 53~ The membranes were then 
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Fig. 1. Map of the human genomic APRT sequence showing phys- 
ical distances between various restriction sites. Closed blocks are 
coding sequences. B, T and Bgl indicate non-polymorphic cut sites 
with BarnH1, Taql and Bglll, respectively. PN-5 and PN-9 indicate 
the locations of sense and anti-sense sequences respectively, used 
for the PCR method. J: APRT*J mutation site 
Determination of  haplotypes 
The human APRT gene is short with 5 separate coding sequences 
spreading over 2.2 kb DNA. A highly polymorphic TaqI restric- 
tion fragment length polymorphism (RFLP) site (hTaq) is located 
within intron 2 of the human APRT gene, whereas a poorly poly- 
morphic TaqI RFLP site (pTaq) is downstream of the gene 
(Fig. 1). The SphI RFLP site (Sph) is located upstream of the 
APRT gene. The Sph and hTaq sites are approximately 3.8 kb and 
1.1 kb, respectively, upstream of the APR T*J mutation site, which 
is in exon 5, whereas pTaq is about 1.0kb downstream of the same 
mutation site (Fig. 1). RFLP sites hTaq (Stambrook et al. 1984) 
and Sph (Arrand et al. 1987), both of which are highly polymorphic 
among Caucasians, have been described. The physical distances 
between restriction sites, B in exon 1, T, hTaq, B in the 3' non- 
coding region, and the mutation site J (Fig. 1), were calculated 
from the published sequence (Broderick et al. 1987; Hidaka et al. 
1987); others were determined by the double digestion procedure. 
For the determination of RFLP patterns, DNA from each indi- 
vidual was digested with either SphI or TaqI, and Southern blot 
analysis was performed by standard procedures using radiolabeled 
cDNA of human APRT. 
Results 
Venous  blood was collected f rom 39 patients with 2,8-di- 
hydroxyaden ine  urolithiasis and f rom 137 control  sub- 
jects, all Japanese .  All o f  the 2 ,8-d ihydroxyadenine  
urolithiasis patients tested were homozygous ly  deficient 
(both alleles are defective) in A P R T ,  as de te rmined  by 
the resistance of  viable T-cells to 6-methylpur ine  (Kama-  
tani et al. 1985). A m o n g  the 39 patients,  9 were  type I 
and 30 were type II ,  as de te rmined  by the enzyme  assay. 
Use  of  the P C R  procedure  and specific oligonuc- 
leotide probes  clearly showed whe ther  each individual 
had the APRT*J or  non-APRT*J alleles (or both) ,  ex- 
cept for rare cases in which amplification of  the target  se- 
quence  was unsuccessful.  The reason for the unsuccess- 
ful amplification was unclear,  but  repea ted  exper iments  
almost  always amplified the target  sequences  of  the same 
samples. Absence  of  hybridizat ion because of  the unsuc- 
cessful amplification of  the specific D N A  sequence could 
be readily distinguished f rom that  caused by the absence 
of the allele in the individual since, in the fo rmer  case, 
the samples hybridized with nei ther  PN-3 nor  PN-4,  
whereas  in the latter, the samples hybridized with either. 
We conf i rmed that  all the 30 type II  patients,  but  none  of  
the 9 type I patients or  97 control  subjects tested, carr ied 
the APRT*J mutat ion  (Fig. 2). Conversely,  samples 
f rom all control  subjects and the 9 type I patients,  but  
not  those f rom 24 out  of  30 type II  patients,  conta ined 
non-APRT*J alleles (Fig. 2). These observat ions  indi- 
cate that  none  of  the type I patients,  but  all the type I I  
patients,  have APRT*J alleles. These  data  also indicate 
that  a small percentage  of  type II  patients (6/30) have 
another  muta t ion  in addit ion to the APRT*J muta t ion  
( compound  heterozygotes) .  These  samples with bo th  
APRT*J and non-APRT*J mutat ions  were excluded 
f rom the present  study to avoid confusion.  
We subjected D N A  samples to Southern  blot analysis 
using a h u m a n  A P R T  c D N A  probe,  the object  being to 
search for RFLPs .  As  shown in the genomic  A P R T  map 
in Fig. 1, there are three R F L P  sites within and near  the 
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F i g . 2 ,  Sequence-specific hybridization of synthetic DNA probes 
with APR T*J and non-APR T*J alleles. After amplification of part 
of genomic APRT sequences by the PCR procedure, the samples 
were dot-blotted onto nylon membranes. Probes, PN-4 (1 probe) 
or PN-3 (J-probe) were end-labeled and hybridized with the blot- 
ted samples. Genotypes are shown in the top block (1/1: APRT*I/ 
APRT*I, l/J: APRT*I/APRT*J, J/J: APRT*J/APRT*J, Q/Q: 
APRT*QO/APRT*QO). X indicates that amplification was unsuc- 
cessful for these samples 
T a b l e  1. Haplotypes of APRT alleles. + indicates that the restric- 
tion enzyme was able to cut the RFLP site, - indicates that it 
failed to cut that site. See Fig. 1 for the location of each RFLP site. 
APRT*I normal allele 
As shown in Table 1, normal alleles had four com- 
mon ( + + + ,  - + + ,  + - +  and - - + )  and two rare 
( -  + - and + - - )  haplotypes. A Z 2 analysis of a 2 • 2 ta- 
ble did not reject the non-association hypothesis (P > 0.1) 
between the two common RFLP sites (Sph and hTaq), 
thereby suggesting that these polymorphisms have been 
present long enough to dissolve the linkage disequi- 
librium. We then tested samples f rom the 24 patients 
with type II  A P R T  deficiency, all of whom possess two 
APRT*J alleles. Among  a total of 48 alleles, 42 (87.5%) 
showed the + - +  haplotype,  whereas the remaining 6 
(12.5%) showed the - - +  haplotype (Table 1). 
One of the 18 APRT*QO alleles showed an aberrant  
band,  as previously reported (Hidaka et al. 1988). In this 
allele, a major  gene alteration can be expected since di- 
gestion of this allele with other restriction enzymes such 
as EcoRI and BamHI also showed aberrant  bands (data 
not shown). All the other APRT*QO alleles showed 
either the + + + (14/17) or - + + (3/17) haplotype,  and 
only these 17 alleles are included in Table 1. 
Our data show that there is a strong linkage disequi- 
librium between the APRT*J mutat ion site and hTaq. 
Thus, although 44% and 56% of the control A P R T  al- 
leles (without the APRT*J mutation) showed hTaq+ 
and hTaq-  RFLPs,  respectively, all the alleles having 
the APRT*J mutat ion showed a hTaq-  RFLP,  thereby 
indicating a strong association between the APR T*J mu- 
tation and the hTaq-  RFLP. ~2 analysis indicates that 
the non-association hypothesis can be rejected (P < 10-7). 
A positive association is also present between the 
APRT*J mutat ion and Sph+ RFLP (P < 10-7). 
RFLP sites Alleles 
Sph hTaq pTaq APRT*I APRT*J APRT*QO 
+ + + 42 0 14 
- + + 4 2  0 3 
+ - + 40 42 0 
- - + 6 8  6 0 
- + - 1 0 0 
+ - - 1 0 0 
Total 194 48 17 
human A P R T  gene, two are highly polymorphic (Sph 
and hTaq), the other only poorly polymorphic (pTaq). 
These highly polymorphic RFLPs were present  before 
racial divergence, as both Caucasian (Stambrook et al. 
1984; Arrand et al. 1987) and Japanese populations have 
the same common RFLPs.  Since familiy studies were not 
per formed on the control subjects, the haplotype of each 
allele could be determined only when an individual was 
heterozygous at less than two RFLP sites. We collected 
a total of 194 such alleles from 137 normal  Japanese sub- 
jects (i.e. 40 were not used as they showed heterozygos- 
ity at more than one RFLP site) (Table 1). Da ta  f rom all 
homozygous A P R T  deficient individuals were included 
here since each was heterozygous at, at most,  one RFLP 
site. 
D i s c u s s i o n  
It is unlikely that mutant  APRT*J alleles have multi- 
ple origins, for the following reasons. (a) If  APRT*J al- 
leles were a reflection of the same disease-causing mu- 
tation that occurred more  than once, then normal al- 
leles with the h T a q -  RFLP should have been the ex- 
clusive targets of the mutations,  even though normal 
alleles have almost equivalent proport ions of the hTaq-  
and hTaq+ RFLPs.  (b) Of  all defective A P R T  alleles 
among the Japanese,  69% are found to be APRT*J, 
but none of the Caucasian A P R T  deficient patients had 
APRT*J alleles; hence multiple APRT*J alleles are 
probably not the result of a hot spot for mutations. 
(c) The presence of a hot spot leading to the APRT*J 
mutat ion also disagrees with the finding that none of 
the in vitro new mutations at the A P R T  locus in human 
B-cells had characteristics of the APRT*J allele (Kama- 
tani et al. 1987a). Therefore ,  the APRT*J alleles from 
different Japanese families probably derive f rom a single 
origin. 
If all APRT*J alleles f rom different Japanese fami- 
lies do indeed derive from a single mutational ancestor 
gene, then these alleles should continue to have the same 
haplotype,  unless additional mutations,  crossover or 
gene conversions have taken place. Since all APRT*J al- 
leles tested had either the + -  + or - -  + haplotype,  the 
possibility that recombinations have not occurred be- 
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tween the APRT*J site and hTaq cannot be ruled out. In 
contrast, crossovers between the APRT*J mutation site 
and Sph, or mutations at Sph should have occurred since 
the association between the APRT*J mutation and the 
Sph+ RFLP is incomplete. When we compare the prob- 
ability that a crossover occurred between the APRT*J 
mutation site and Sph (3.8 kb apart) with the probability 
that a point mutation destroying the Sphl recognition se- 
quence occurred, the former (approximately 3.8 x 10 .5 
per generation, if the rate of recombination is 10 .8 per 
bp per generation; Cox et al. 1985) is much higher than 
the latter (approximately 6 x 10 -s per generation, if we 
assume that the rate of point mutation is 10 -8 per bp per 
generation; Neel et al. 1986). 
In the case of PI Z alleles, which cause an al-anti- 
trypsin deficiency in Caucasians, only 1/52 of the PI Z al- 
leles reflected a possible crossover between two RFLP 
sites (about 9 kb apart) near the PI Z mutation site (Cox 
et al. 1985), clearly indicating that they are of a single 
origin. Assuming that there is one meiotic crossover per 
10 s base pairs per generation, the authors calculated that 
216 generations, or 6480 years, would be required to 
generate 1.9% crossovers. Assuming that all APRT*J 
alleles have a single origin, we calculated, by the method 
of Bodmer (1972), how long it would take for the linkage 
disequilibrium (A) to decrease to the current level. We 
assumed that, at generation 0, all APRT*J alleles had a 
Sph+ RFLP, and the frequency of APRT*J alleles (p) 
and that of Sph+ alleles (83/194 = 0.428) in the popula- 
tion have not changed since generation 0. At  generation 
0, A was p -0 .428p  = 0.572p (A1), but now (generation 
n), it is p(42/48-0.428) = 0.447p (A2). Therefore, if the 
recombination fraction (0) between the APRT*J 
mutation site and Sph (3.8 kb apart) is 3.8 x 10-5/genera - 
tion, then: (1-0) n = (1-3.8 x 10-~) n = (AJA1) = 0.447p/ 
0.572/) = 0.781. Therefore, the number of generations 
(n) required for A to decrease from 0.572p to 0.447/) will 
be: n = 6505 
Thus, according to this method, the age of the 
APRT*J mutation is calculated to be 6505 generations 
or 130092 years (one generation was assumed to be 20 
years). 
The APRT*J mutation calculated here is surprisingly 
old; it is much older than the ages of the [3S-globin muta- 
tion (1000-2000 years; Bunn and Forget 1986) and the 
PI Z mutation (6480 years). In the case of the PI Z mu- 
tation, the distance between the polymorphic marker 
and the mutation site was longer and the percentage 
of the recombinant alleles was smaller than in the 
APRT*J mutation. Another piece of evidence suggest- 
ing the old age of the APRT*J mutation is a nucleotide 
difference found in intron 2 between two different 
APRT*J alleles (Hidaka et al. 1988). 
There are several inaccurate values in the calculation 
of the age of the APRT*J mutation. For example, the 
rate of recombination between Sph and the APRT*J 
mutation site may be higher than the average. Indeed, 
3-30 fold and 24 fold higher than the average rate of 
crossovers have been described near the ]3-globin gene 
(Chakravarti et al. 1984) and the insulin gene (Chak- 
ravarti et a1.1986), respectively. If the crossover rates 
were 3 fold and 30 fold higher than the average, then the 
calculated age of the APR T*J mutation would be 43 360 
years (2168 generations) and 4340 years (217 genera- 
tions), respectively. 
Although the procedures for calculating the ages of 
mutations from linkage disequilibrium are not likely to 
lead to accurate values, it does nevertheless seem that 
the APRT*J mutation has a long history. Indeed, the 
validity of the data presented here can be tested by 
analyzing mutational APRT alleles in other ethnic 
groups, especially in Asians. Since the detection of het- 
erozygotes for the APRT*J mutation is not difficult, 
such investigations are feasible. 
The presence of the same mutations in many separate 
families has been noted in other clinical entities. Thus, in 
hemoglobinopathies (Weatherall et al. 1989), thalasse- 
mias (Weatherall et al. 1989), Gauscher's disease (Tsuji 
et al. 1987) and phenylketonuria (DiLella et al. 1987), 
the same mutant genes in each ethnic group often have 
the same haplotype, and hence may derive from a single 
mutation. In addition, recent investigations have shown 
that about 69% of the cystic fibrosis genes among Cauca- 
sians have a single mutation, and that these mutant 
genes may have a single origin (Riordan et al. 1989). 
Since cystic fibrosis is present widely in Europe and is in 
about 5% of the normal Caucasian population, this spe- 
cial mutant gene is also likely to have an ancient origin. 
At least in the case of sickle cell anemia, compensating 
advantages play an important role (Weatherall et al. 
1989), but in many other diseases, it is controversial 
whether the compensating advantage, a founder effect 
or random genetic drift (Ohta 1973) is responsible for 
amplification and retention of disease-causing genes. 
With regard to APRT*J, evidence for or against com- 
pensating advantage is not available. To examine vari- 
ous hypotheses regarding the roles of deleterious genes 
in evolution, it is important to expand our knowledge of 
the historical fate of disease-causing genes in general. 
Historical documents have been useful in such cases, in- 
cluding Tay-Sachs gene(s) among the antecedents of 
modern Ashkenazi Jewry (Petersen et al. 1983) and por- 
phyria variegata among Afrikaners in South Africa 
(Diamond and Rotter et al. 1987). However, such a 
strategy is of limited value, especially when mutant 
genes have persisted for long periods of time. A more 
practical method is to investigate the histories of disease- 
causing mutations, based on molecular biological data. 
Our data suggest that some disease-causing genes persist 
in some populations for unexpectedly long periods. 
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